Cancers, Vol. 12, Pages 800: A Nine-Gene Signature for Predicting the Response to Preoperative Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer
In this study, we performed a gene expression study using formalin-fixed paraffin-embedded (FFPE) tumor biopsy samples from 156 LARC patients (training cohort n = 60; validation cohort n = 96); we identified the nine-gene signature (FGFR3, GNA11, H3F3A, IL12A, IL1R1, IL2RB, NKD1, SGK2, and SPRY2) that distinctively differentiated responders from non-responders in the training cohort (accuracy = 86.9%, specificity = 84.8%, sensitivity = 81.5%) as well as in an independent validation cohort (accuracy = 81.0%, specificity = 79.4%, sensitivity = 82.3%). The signature was independent of all pathological and clinical features and was robust in predicting PCRT response. It is readily applicable to the clinical setting using FFPE samples and Food and Drug Administration (FDA) approved hardware and reagents. Predicting the response to PCRT may aid in tailored therapies for respective responders to PCRT and improve the oncologic outcomes for LARC patients.
Source: Cancers - Category: Cancer & Oncology Authors: In Ja Park Yun Suk Yu Bilal Mustafa Jin Young Park Yong Bae Seo Gun-Do Kim Jinpyo Kim Chang Min Kim Hyun Deok Noh Seung-Mo Hong Yeon Wook Kim Mi-Ju Kim Adnan Ahmad Ansari Luigi Buonaguro Sung-Min Ahn Chang-Sik Yu Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Genetics | Rectal Cancers | Study | Training | Universities & Medical Training